The reported statements, read against the company's own industry.
Financials view
Market Capitalization
400.49MUSD
vs all stocks (USD)
Updated Oct 26, 2026
Revenue (TTM)
74.84MUSD
vs all stocks (USD)
Updated Oct 26, 2026
Profit Margin
-0.06%
vs Biotechnology peers
Updated Oct 26, 2026
Beta
1.16x
vs all stocks
Updated Oct 26, 2026
52-Week Change
-33.99%
vs all stocks
Updated Oct 26, 2026
Forward Annual Dividend Yield
0.00%
vs all stocks
Updated Oct 26, 2026
Market Capitalization
400.49MUSD
vs all stocks (USD)
Updated Oct 26, 2026
Enterprise Value
85.94MUSD
vs all stocks (USD)
Updated Oct 26, 2026
Forward P/E
-7.71x
vs Biotechnology peers
Updated Oct 26, 2026
Price to Sales (TTM)
5.40x
vs Biotechnology peers
Updated Oct 26, 2026
Price to Book (MRQ)
1.29x
vs Biotechnology peers
Updated Oct 26, 2026
Enterprise to Revenue
1.15x
vs Biotechnology peers
Updated Oct 26, 2026
Enterprise to EBITDA
-9.89x
vs Biotechnology peers
Updated Oct 26, 2026
Profit Margin
-0.06%
vs Biotechnology peers
Updated Oct 26, 2026
Operating Margin
-47.44%
vs Biotechnology peers
Updated Oct 26, 2026
Return on Assets (TTM)
-2.67%
vs Biotechnology peers
Updated Oct 26, 2026
Return on Equity (TTM)
-0.03%
vs Biotechnology peers
Updated Oct 26, 2026
Revenue (TTM)
74.84MUSD
vs all stocks (USD)
Updated Oct 26, 2026
Revenue per Share (TTM)
4.57USDUpdated Oct 26, 2026
Quarterly Revenue Growth
38.90%
vs Biotechnology peers
Updated Oct 26, 2026
Gross Profit (TTM)
11.19MUSD
vs all stocks (USD)
Updated Oct 26, 2026
EBITDA (TTM)
-8.69MUSD
vs all stocks (USD)
Updated Oct 26, 2026
Net Income (TTM)
-42.00KUSD
vs all stocks (USD)
Updated Oct 26, 2026
Quarterly Earnings Growth (YoY)
38.94%
vs Biotechnology peers
Updated Oct 26, 2026
Operating Cash Flow (TTM)
-38.48MUSD
vs all stocks (USD)
Updated Oct 26, 2026
Levered Free Cash Flow (TTM)
-27.87MUSD
vs all stocks (USD)
Updated Oct 26, 2026
Forward Annual Dividend Yield
0.00%
vs all stocks
Updated Oct 26, 2026
Trailing Annual Dividend Rate
0.00USDUpdated Oct 26, 2026
Trailing Annual Dividend Yield
0.00%
vs all stocks
Updated Oct 26, 2026
Payout Ratio
0.00%
vs Biotechnology peers
Updated Oct 26, 2026
Revenue
72.30MUSDFY2025 · Dec 31, 2025
Operating Income
-12.12MUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
-6.12MUSDFY2025 · Dec 31, 2025
Income Tax Expense
0.00USDFY2025 · Dec 31, 2025
Net Income
-6.12MUSDFY2025 · Dec 31, 2025
EBIT
-12.12MUSDFY2025 · Dec 31, 2025
EBITDA (Income Statement)
-11.99MUSDFY2025 · Dec 31, 2025
Research & Development
64.81MUSDFY2025 · Dec 31, 2025
Selling, General & Administrative
19.61MUSDFY2025 · Dec 31, 2025
Non-operating Interest Income
6.00MUSDFY2025 · Dec 31, 2025
EPS (Basic)
-0.5500USDFY2025 · Dec 31, 2025
EPS (Diluted)
-0.5500USDFY2025 · Dec 31, 2025
Basic Shares Outstanding
11.21MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
11.21MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
-6.12MUSDFY2025 · Dec 31, 2025
Operating Cash Flow
-37.70MUSDFY2025 · Dec 31, 2025
Free Cash Flow
-37.77MUSDFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
58.45MUSDFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
-6.12MUSDFY2025 · Dec 31, 2025
Depreciation & Amortization
129.00KUSDFY2025 · Dec 31, 2025
Stock-based Compensation
4.68MUSDFY2025 · Dec 31, 2025
Other Non-cash Items
851.00KUSDFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
-974.00KUSDFY2025 · Dec 31, 2025
Change in Accounts Payable (CF)
586.00KUSDFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
-36.85MUSDFY2025 · Dec 31, 2025
Capital Expenditures
-66.00KUSDFY2025 · Dec 31, 2025
Purchase of Investments
-229.83MUSDFY2025 · Dec 31, 2025
Sale of Investments
116.43MUSDFY2025 · Dec 31, 2025
Net Investing Cash Flow
-113.47MUSDFY2025 · Dec 31, 2025
Net Financing Cash Flow
168.31MUSDFY2025 · Dec 31, 2025
Shares Outstanding
19.85MSharesUpdated Oct 26, 2026
Float Shares
9.17MSharesUpdated Oct 26, 2026
Shares Short
2.82MSharesUpdated Oct 26, 2026
Short Ratio
7.57days
vs all stocks
Updated Oct 26, 2026
Short % of Shares Outstanding
18.45%
vs all stocks
Provider-reported. Shares Short ÷ Shares Outstanding on this page gives 14.22%.Updated Oct 26, 2026
% Held by Insiders
27.66%
vs all stocks
Updated Oct 26, 2026
% Held by Institutions
69.68%
vs all stocks
Updated Oct 26, 2026
Total Cash (MRQ)
320.36MUSD
vs all stocks (USD)
Updated Oct 26, 2026
Total Cash per Share (MRQ)
15.73USDUpdated Oct 26, 2026
Total Debt (MRQ)
2.35MUSD
vs all stocks (USD)
Updated Oct 26, 2026
Total Debt to Equity (MRQ)
0.0077x
vs Biotechnology peers
Updated Oct 26, 2026
Current Ratio (MRQ)
13.99x
vs Biotechnology peers
Updated Oct 26, 2026
Book Value per Share (MRQ)
15.40USDUpdated Oct 26, 2026
Total Assets
257.59MUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
254.55MUSDFY2025 · Dec 31, 2025
Total Liabilities
50.84MUSDFY2025 · Dec 31, 2025
Total Non-current Assets
3.04MUSDFY2025 · Dec 31, 2025
Total Non-current Liabilities
2.06MUSDFY2025 · Dec 31, 2025
Total Current Liabilities
48.78MUSDFY2025 · Dec 31, 2025
Cash & Cash Equivalents
58.45MUSDFY2025 · Dec 31, 2025
Other Short-term Investments
189.66MUSDFY2025 · Dec 31, 2025
Accounts Receivable
974.00KUSDFY2025 · Dec 31, 2025
Accounts Payable
1.17MUSDFY2025 · Dec 31, 2025
Short-term Debt
569.00KUSDFY2025 · Dec 31, 2025
Deferred Revenue
36.90MUSDFY2025 · Dec 31, 2025
Long-term Debt
2.06MUSDFY2025 · Dec 31, 2025
Common Stock (Book)
16.00KUSDFY2025 · Dec 31, 2025
Retained Earnings
-832.05MUSDFY2025 · Dec 31, 2025
Total Shareholders' Equity
206.75MUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
52-Week Low
19.30USDUpdated Oct 26, 2026
52-Week High
39.71USDUpdated Oct 26, 2026
52-Week Change
-33.99%
vs all stocks
Updated Oct 26, 2026
Beta
1.16x
vs all stocks
Updated Oct 26, 2026
50-Day MA
27.36USDUpdated Oct 26, 2026
200-Day MA
27.48USDUpdated Oct 26, 2026
Avg 10-Day Volume
212.72KSharesUpdated Oct 26, 2026
Avg 30-Day Volume
318.03KSharesUpdated Oct 26, 2026
Diluted EPS (TTM)
1.04USDUpdated Oct 26, 2026
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 1.29: grey zoneSignificant
Altman Z-Score: 1.29
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.